0000000000785382

AUTHOR

T Gamstätter

showing 3 related works from this author

949 IDENTIFICATION OF TWO CLINICALLY DISTINCT SUBTYPES IN AUTOIMMUNE HEPATITIS BY COMPARATIVE FUNCTIONAL GENOMICS

2013

Conclusion: Incidence of autoimmune hepatitis is increasing, as other autoimmune diseases in developed countries. The main recognised hypothesis is the ‘hygienist theory’ (improvement of hygien leading to a decrease in infections) with few putative non exclusive mechanisms involving antigenic competition, extension of immune regulation induced by exogenous bacterial antigen or Toll Like Receptors.

HepatologyAntigenImmunologyImmune regulationmedicineIdentification (biology)Autoimmune hepatitisBacterial antigenBiologyReceptorBioinformaticsmedicine.diseaseFunctional genomicsJournal of Hepatology
researchProduct

Survival of patients with unresectable cholangiocarcinoma undergoing palliative chemotherapy - real world data from a German tertiary care center

2021

Germanmedicine.medical_specialtybusiness.industryGeneral surgerymedicinelanguageCenter (algebra and category theory)Palliative chemotherapybusinessReal world dataTertiary carelanguage.human_languageViszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV)
researchProduct

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sor…

2013

Abstract Background Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Aims/methods Univariate/multivariate analyses were conducted to identify retrospectively the impact of baseline characteristics on the survival of 110 patients with advanced HCC treated with sorafenib. Results Median survival of the whole cohort was 6.7 months, median survival in Child-Pugh A, B, C patients was 10.5, 6.1 and 3.0 months and median survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C/D was 6.8/2.6 months. Presence of ascites, presence of macrovascular invas…

OncologySorafenibAdultMaleNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularAntineoplastic AgentsSeverity of Illness IndexYoung AdultInternal medicineAscitesmedicineHumansAgedRetrospective StudiesAged 80 and overHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsGastroenterologyMiddle AgedSorafenibmedicine.diseasePrognosisSurvival Analysisdigestive system diseasesBCLC StageTreatment OutcomeHepatocellular carcinomaMultivariate AnalysisFemaleLiver functionmedicine.symptomLiver cancerbusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct